Xeris Biopharma Holdings, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 10.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.96B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Details
| Name | Xeris Biopharma Holdings, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 435 |
| Founded | 2005 |
| Ipo Date | 2018-06-21 |
| Ceo | John Shannon |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US98422E1038 |
| Cusip | 98422E103 |
| Cik | 0001867096 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| John P. Shannon | Chairman and Chief Executive Officer |
| Kevin McCulloch | President and Chief Operating Officer |
| Steven M. Pieper | Chief Financial Officer |
| Beth P. Hecht J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer |
| Brian Conner | SVice President of Quality and Chief Compliance and Risk Officer |
| Kendal Korte | Senior Vice President of Human Resources |
| Joshua Bennett | Vice President of Strategy and Business Development |
Contact
| Address | 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607, United States |
| Phone | 844 445 5704 |
| Website | https://www.xerispharma.com |